首页> 外文OA文献 >Solitomab, an epithelial cell adhesion molecule/CD3 bispecific antibody (BiTE), is highly active against primary chemotherapy-resistant ovarian cancer cell lines in vitro and fresh tumor cells ex vivo

【2h】

Solitomab, an epithelial cell adhesion molecule/CD3 bispecific antibody (BiTE), is highly active against primary chemotherapy-resistant ovarian cancer cell lines in vitro and fresh tumor cells ex vivo

机译：Solitomab，上皮细胞粘附分子/ CD3双特异性抗体（咬合）是对体外和新鲜肿瘤细胞的主要化疗抗性卵巢癌细胞系高度活跃

代理获取

本网站仅为用户提供外文OA文献查询和代理获取服务，本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文，但由于OA文献来源多样且变更频繁，仍可能出现获取不到、文献不完整或与标题不符等情况，如果获取不到我们将提供退款服务。请知悉。

页面导航

著录项
引文网络
相似文献
相关主题

著录项

作者
Diana P. English; Stefania Bellone; Carlton L. Schwab; Dana M. Roque; Salvatore Lopez; Ileana Bortolomai; Emiliano Cocco; Elena Bonazzoli; Sudeshna Chatterjee; Elena Ratner; Dan-Arin Silasi; Masoud Azodi; Peter E. Schwartz; Thomas J. Rutherford; Alessandro D. Santin;
展开▼
作者单位

展开▼
年度 2014
总页数
原文格式 PDF
正文语种
中图分类

相似文献

外文文献
中文文献
专利

1. Solitomab, an Epithelial Cell Adhesion Molecule/CD3 Bispecific Antibody (BiTE), Is Highly Active Against Primary Chemotherapy-Resistant Ovarian Cancer Cell Lines In Vitro and Fresh Tumor Cells Ex Vivo [J] . English Diana P., Bellone Stefania, Schwab Carlton L., Cancer: A Journal of the American Cancer Society . 2015,第3期

机译：Solitomab是一种上皮细胞粘附分子/ CD3双特异性抗体（BiTE），对原发性耐药化疗的卵巢癌细胞系和体外新鲜肿瘤细胞具有高活性
2. Solitomab, an Epithelial Cell Adhesion Molecule/CD3 Bispecific Antibody (BiTE), Is Highly Active Against Primary Chemotherapy-Resistant Ovarian Cancer Cell Lines In Vitro and Fresh Tumor Cells Ex Vivo [J] . English Diana P., Bellone Stefania, Schwab Carlton L., Cancer: A Journal of the American Cancer Society . 2015,第3期

机译：Solitomab，上皮细胞粘附分子/ CD3双特异性抗体（咬合），对体外和新鲜肿瘤细胞的原发性化疗抗性卵巢癌细胞系具有高度活跃
3. Basic Science Ovarian Cancer Solitomab, an EpCAM/CD3 bispecific antibody (BITE), is highly active against primary chemotherapy resistant ovarian cancer cell lines in vitro and fresh tumor cells ex vivo [J] . English Diana P., Bellone Stefania, Schwab Carlton L., Gynecologic Oncology: An International Journal . 2015,第2期

机译：基础科学卵巢癌Solitomab，EpCAM / CD3双特异性抗体（BITE），在体外和原代新鲜肿瘤细胞中对原发性化疗耐药性卵巢癌细胞系具有高活性
4. Small Molecule ONC201/TIC10 Targets Chemotherapy-Resistant Colorectal Cancer Stem Cells In Vitro and In Vivo [C] . Varun Vijay Prabhu, Joshua E. Allen, David T. Dicker, Molecular Medicine TRI-CON. . 2014

机译：小分子ONC201 / TIC10在体外和体内靶向化疗抗性结肠直肠癌干细胞
5. Comparative pharmacology of the human CD19/CD3 Bispecific T-cell engager (BiTERTM) antibody blinatumomab with the hybrid murine surrogate CD19/CD3 BiTE antibody hyS103. [D] . Fuhrmann, Stacy R. 2010

机译：人CD19 / CD3双特异性T细胞衔接子（BiTERTM）抗体blinatumomab与杂种鼠替代CD19 / CD3 BiTE抗体hyS103的比较药理学。
6. Solitomab an EpCAM/CD3 bispecific antibody (BiTE®) is highly active against primary chemotherapy resistant ovarian cancer cell lines in vitro and fresh tumor cells ex vivo [O] . Diana P. English, Stefania Bellone, Carlton L. Schwab, -1

机译：Solitomab一种EpCAM / CD3双特异性抗体（BiTE®）对体外抗原发性化疗的卵巢癌细胞系和离体新鲜肿瘤细胞具有高活性
7. Solitomab, an EpCAM/CD3 bispecific antibody construct (BiTE®), is highly active against primary uterine and ovarian carcinosarcoma cell lines [O] . 2015

机译：Solitomab，EpCAM / CD3双特异性抗体构建体（BiTE®），对原发性子宫和卵巢癌肉瘤细胞系具有高活性

Solitomab, an epithelial cell adhesion molecule/CD3 bispecific antibody (BiTE), is highly active against primary chemotherapy-resistant ovarian cancer cell lines in vitro and fresh tumor cells ex vivo

著录项

引文网络

相似文献

相关主题

期刊订阅